Galapagos NV (ADR)
General ticker "GLPG" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.9B (TTM average)
Galapagos NV (ADR) follows the US Stock Market performance with the rate: 52.1%.
Estimated limits based on current volatility of 0.6%: low 31.52$, high 31.92$
Factors to consider:
- Total employees count: 435 as of 2015
- Current price 17.5% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [11.44$, 27.04$]
- 2025-12-31 to 2026-12-31 estimated range: [8.80$, 20.94$]
Financial Metrics affecting the GLPG estimates:
- Positive: with PPE of 178.0 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -18.62 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Positive: Interest expense per share per price, % of 0.05 <= 0.79
Short-term GLPG quotes
Long-term GLPG plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €241.25MM | €239.72MM | €275.65MM |
| Operating Expenses | €372.31MM | €327.99MM | €463.99MM |
| Operating Income | €-131.06MM | €-88.26MM | €-188.34MM |
| Non-Operating Income | €60.21MM | €93.89MM | €185.25MM |
| Interest Expense | €9.15MM | €1.65MM | €0.91MM |
| R&D Expense | €269.80MM | €241.29MM | €335.46MM |
| Income(Loss) | €-70.85MM | €5.62MM | €-3.08MM |
| Taxes | €0.57MM | €9.61MM | €-1.80MM |
| Profit(Loss)* | €-217.99MM | €-3.99MM | €74.08MM |
| Stockholders Equity | €2,526.03MM | €2,795.57MM | €2,896.94MM |
| Inventory | €52.92MM | €73.98MM | €51.19MM |
| Assets | €4,734.35MM | €4,357.40MM | €4,135.72MM |
| Operating Cash Flow | €-500.54MM | €-405.97MM | €-320.03MM |
| Capital expenditure | €36.95MM | €19.27MM | €82.11MM |
| Investing Cash Flow | €-1,245.51MM | €71.19MM | €220.60MM |
| Financing Cash Flow | €-1.49MM | €-5.00MM | €-4.92MM |
| Earnings Per Share** | €-3.32 | €-0.06 | €1.12 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.